This study was designed to evaluate anti-Xa activity hourly during the first 3 h after a single intravenous bolus of 0.5 mg/kg enoxaparin in 30 patients with end-stage renal disease (ESRD) who underwent haemodialysis, and in 30 patients with normal or mildly reduced renal function who underwent coronary angiography for chest pain (non-ESRD group). Mean ± SD haemodialysis time was 3.9 ± 0.3 h in the ESRD group. Of 24 patients diagnosed with coronary artery disease in the non-ESRD group, 20 underwent percutaneous coronary intervention (PCI). A peak anti-Xa activity > 0.5 IU/ml 10 min after enoxaparin injection was obtained in 90% and 93% of the non-ESRD and ESRD patients, respectively. The percentages of patients with peak anti-Xa activity in the target range (0.5 -1.5 IU/ml) were similar in the two groups (non-ESRD 80%, ESRD 93%). Adequate anti-Xa activity (> 0.5 IU/ml) lasted about 2 h in both groups. It is concluded that a single intravenous lowdose enoxaparin (0.5 mg/kg) bolus provides anti-Xa activity adequate for elective PCI within 2 h irrespective of whether or not the patient had ESRD.
Introduction
Unfractionated heparin (UFH) has been the primary anticoagulant therapy for the percutaneous coronary intervention (PCI) procedure for the past two decades, but the correlation between the optimal dose of UFH and the activated clotting time remains unsatisfactory. 1, 2 In many catheterization laboratories, the standard procedure after PCI using UFH requires 4 h of bed rest before sheath removal and manual compression of the femoral artery puncture site. A single intravenous bolus of low-dose (0.5 mg/kg) enoxaparin has been found to provide adequate anticoagulation within 2 -3 h without dose adjustment in patients with normal or reduced renal function (creatinine clearance ≥ 60 or < 40 ml/min, respectively) Intravenous enoxaparin in ESRD who received an elective PCI procedure, and appears to be safe for immediate sheath removal and manual compression. 3 -5 Activity against blood-clotting factor Xa in patients with end-stage renal disease (ESRD) given such a dose of enoxaparin by the same route has not previously been investigated.
Patients with ESRD have a cardiovascular mortality rate that is 15 -30 times higher than that of the age-adjusted general population and approximately 50% of individuals with ESRD die from a cardiovascular cause. 6, 7 Thus, ESRD patients are a major target population for coronary intervention. 8 Because enoxaparin is cleared principally by the renal route and its half-life is longer in patients with renal failure than in healthy subjects, 9 concern has been raised about the higher anti-Xa activity in patients with severe renal insufficiency (creatinine clearance < 30 ml/min) and ESRD. 10,11 The present study was designed to evaluate anti-Xa activity hourly for the first 3 h during a haemodialysis session after administration of an intravenous bolus of 0.5 mg/kg enoxaparin in patients with ESRD and also to investigate the changes in anti-Xa activity during this 3-h period in patients with normal or mildly reduced renal function (non-ESRD patients) and who underwent elective coronary angiography because of chest pain.
Patients and methods

STUDY POPULATION
Patients who were > 20 years of age with or without ESRD were enrolled into this study between July and November 2008. Those with ESRD (the ESRD group) had a creatinine level ≥ 8 mg/dl, underwent regular haemodialysis and were excluded from the study if they had been diagnosed with acute cardiovascular or cerebrovascular disease within the previous 3 months. Patients without ESRD (the non-ESRD group) had normal or mildly reduced renal function (creatinine level ≤ 2 mg/dl) and were admitted for elective coronary angiography because of chest pain. Patients without ESRD were excluded if they had been admitted to the cardiac care unit for initial medical therapy, or had received low-molecularweight heparin or UFH within the last 48 h before PCI.
The study was approved by the Institutional Review Board of Taoyuan General Hospital and all patients provided written informed consent before participating in the study.
PROCEDURE IN ESRD PATIENTS (HAEMODIALYSIS)
All patients in the ESRD group underwent routine haemodialysis using a high-flux polysulphone membrane (TS1.8; Toray, Tokyo, Japan) with an ultra-filtration coefficient of 50 ml/h per mmHg. The blood flow rate was 250 ml/min and the dialysate flow rate was 500 ml/min. According to our standard dialysis procedure, the extra-corporeal circuit was rinsed with 500 ml of heparinized saline, which was discarded before the line was connected to the patient. Blood for the measurement of baseline anti-Xa activity was taken from the afferent line before the administration of enoxaparin. An intravenous bolus of 0.5 mg/kg enoxaparin was administered at the start of dialysis through the afferent line of the dialyser. Other blood samples for measurement of anti-Xa activity were taken from the efferent lines at 10 min, 1 h, 2 h and 3 h after the bolus injection.
PROCEDURE IN NON-ESRD PATIENTS (ELECTIVE CORONARY ANGIOGRAPHY)
For all patients in the non-ESRD group, percutaneous 6F sheaths were inserted using a radial or femoral artery approach. An JS Lin, WJ Wang, WC Lin et al.
Intravenous enoxaparin in ESRD
intravenous bolus of 1500 U heparin was administered before coronary angiography. After coronary angiography, which was performed using low-osmolality contrast medium in multiple projections, a blood sample was taken for baseline measurement of anti-Xa activity and an intravenous bolus of enoxaparin (0.5 mg/kg) was then given. Further blood samples for measurement of anti-Xa activity were taken 10 min, 1 h, 2 h and 3 h after injection of the bolus.
Coronary artery disease (CAD) was defined as a coronary stenosis of ≥ 50% in at least one of the three coronary arteries or their primary branches. PCI was performed if the coronary stenosis was > 70% and approachable; there was no further attempt to titrate the enoxaparin dose. A loading dose of 300 mg clopidogrel was administered immediately after stenting, except in patients who had already previously been receiving clopidogrel at 75 mg/day. Patients with CAD were also given 100 mg/day aspirin.
During hospitalization, all patients in the non-ESRD group were routinely monitored for adverse clinical events (death, myocardial infarction, urgent target vessel revascularization, bleeding complications and vascular complications). Myocardial infarction was defined as recurrent chest pain and/or electrocardiogram changes with at least one of the following: troponin I > 2 µg/ml; creatinine kinase more than twice the upper limit of normal and > 25% higher than the previous value; and the appearance of a new left bundle branch block or new Q waves. Urgent target vessel revascularization was defined as the requirement for urgent PCI or coronary bypass grafting necessitated by recurrent ischaemia of the target vessel. The definitions of bleeding events were modified from the criteria used in the ESSENCE Study 12 and those used by Choussat et al. 5 Major bleeding included at least one of the following features: (i) bleeding resulting in death or requiring surgery;
(ii) intra-cranial haemorrhage; (iii) a fall in the serum haemoglobin level of ≥ 3 g/dl; or (iv) the requirement for transfusion of ≥ 2 U of packed red blood cells or whole blood. Minor bleeding was any clinically important bleeding that did not qualify as major bleeding. Vascular complications were categorized as minor or major. Minor complications included any bleeding or oozing from the puncture site in the ward that was controllable by manual compression, as well as infections that were treatable with oral antibiotics. Major complications included vascular surgery, haemorrhage requiring transfusion, stable or expanding haematoma > 3 cm, arterial occlusion or distal arterial embolism, and infections that were treatable only by the intravenous administration of antibiotics or debridement.
BLOOD SAMPLING AND LABORATORY MEASUREMENTS
For both groups, serial blood samples were taken to measure levels of anti-Xa activity before administration of the intravenous bolus of enoxaparin, and 10 min, 1 h, 2 h and 3 h afterwards. Adequate anticoagulation was predefined as a peak of anti-Xa activity between 0.5 and 1.5 IU/ml 10 min after the intravenous bolus of enoxaparin. 5 Blood was collected into Vacutainer ® tubes (Becton Dickinson, Plymouth, UK) containing 0.129 M trisodium citrate. Platelet-poor plasma was obtained by centrifugation at 2000 g at 10°C for 15 min. Plasma anti-Xa activity was determined using the HemosIL™ heparin kit (Instrumentation Laboratory, Lexington, KY, USA) according to the manufacturer's instruction.
STATISTICAL ANALYSIS
Data are expressed as mean ± SD. The two JS Lin, WJ Wang, WC Lin et al. 
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Results
In total, 60 patients were included in the study (30 patients each in the ESRD and non-ESRD groups). The clinical characteristics of the study population are shown in Table 1 . There were significant differences between the groups in body mass index (P < 0.001), number of patients with diabetes (P = 0.004), and in creatinine (P < 0.001) and haemoglobin (P < 0.001) levels. The ESRD group had a mean ± SD haemodialysis time of 3.9 ± 0.3 h and volume reduction of 2.7 ± 1.0 l. In the non-ESRD group, 25 and five patients underwent a radial and a femoral artery approach, respectively. Twenty-four patients were diagnosed as having CAD (five with one-vessel disease, eight with two-vessel disease and 11 with three-vessel disease). Of these, 20 patients underwent PCI (10 for one vessel, nine for two vessels and one for three vessels), and, of the 20 patients who underwent PCI, 15 underwent stenting (10 with a single stent and five with double stents). The mean ± SD time from the intravenous bolus of enoxaparin to the end of balloon angioplasty or stenting was 40 ± 12 min; the longest time was 65 min. During hospitalization, there were no deaths, myocardial infarctions, urgent target vessel revascularizations, bleeding events or vascular complications in the non-ESRD group.
The measurements of anti-Xa activity in the study population are shown in Table 2 . Compared with the ESRD group, the non-ESRD group had higher plasma levels of anti-Xa activity 10 min (P = 0.003) and 1 h (P = 0.024) after intravenous administration of the enoxaparin bolus. Peak (10 min after the intravenous bolus) anti-Xa activity > 0.5 IU/ml occurred in similar percentages of patients in the two groups (non-ESRD 90%, ESRD 93%). The percentages of patients who had peak anti-Xa activity in the target range of 0.5 -1.5 IU/ml were also similar in the two groups (non-ESRD 80%, ESRD 93% at 10 min after the intravenous bolus). Adequate anti-Xa activity (> 0.5 IU/ml) for the elective PCI procedure lasted about 2 h in both groups. 
Discussion
Although UFH is the primary anticoagulant used during elective PCI, it is associated with some issues, such as a variable relationship between UFH dose and activated clotting time, and the need for prolonged bed rest as a result of the femoral artery approach. 1, 2 Studies have shown that intravenous administration of low-dose enoxaparin (0.5 mg/kg) offers more consistent anticoagulant efficacy and shorter bed rest compared with UFH in patients undergoing elective PCI. 3,5 Choussat et al. 5 found a peak anti-Xa activity of > 0.5 IU/ml in 97.5% of 242 patients (mean ± SD 0.88 ± 0.31 IU/ml 10 min after intravenous injection of enoxaparin), and 94.6% of patients had a peak anti-Xa activity in the target range of 0.5 -1.5 IU/ml at the end of elective PCI (< 3 h), confirming a high and constant degree of anticoagulation. The STEEPLE (Safety and Efficacy of Enoxaparin in PCI patients) trial 4 also revealed that, in elective PCI, the percentage of individuals achieving the pre-specified target range of anti-Xa activity (0.5 -1.8 IU/ml) among patients receiving 0.5 mg/kg enoxaparin was significantly higher than the percentage achieving the target activated clotting time (300 -350 s) among patients receiving UFH (78.8% versus 19.7%, respectively; P < 0.001). In contrast, in a smaller study conducted by Zalc et al., 13 a low peak anti-Xa activity of 0.56 ± 0.16 IU/ml was found in 53 South American patients, 12 of whom (23.5%) had peak anti-Xa activity < 0.5 IU/ml. The possible effect of a racial difference (Europeans versus South Americans) was raised at the time of that study. In the present study (in Asian patients), the peak anti-Xa activity and the percentage of patients within the therapeutic range were similar to those reported by Choussat et al. 5 and by the STEEPLE trial, 4 and any racial difference was Although the prolonged renal clearance of subcutaneously injected enoxaparin in patients with severe renal insufficiency (creatinine clearance < 30 ml/min) has caused some concern, 10 Choussat et al. 5 showed that there was no difference in anti-Xa activity between patients with and without renal dysfunction (creatinine clearance < 40 ml/min) in the first 3 h after an intravenous low-dose bolus of enoxaparin. The rare bleeding complications in this pioneer study by Choussat et al. 5 were not related to either renal dysfunction or anti-Xa activity. The subanalysis of the STEEPLE trial 4 also demonstrated that the same intravenous dose of enoxaparin was associated with a trend for less major bleeding compared with UFH in patients with renal impairment (creatinine clearance ≤ 60 ml/min). This information should further diminish any concern about the bleeding tendency associated with the use of intravenous enoxaparin in patients with renal failure. There are, however, very few data on the pharmacokinetics of enoxaparin in patients with ESRD. After a single injection of enoxaparin (0.6 mg/kg) at the start of the dialysis session in 30 patients with chronic haemodialysis, Guillet et al. 11 took three blood samples and used a population approach (non-linear mixed effects modelling) to evaluate the change in anti-Xa activity over a period of 48 h. 11 Two samples were taken, with different sampling times in different patients, during the first 4 h of the dialysis session and one sample was taken after the end of the session, up to 48 h after enoxaparin injection. Anti-Xa activity was > 1.2 IU/ml during the first 2 h, between 0.4 and 1.2 IU/ml at 3 h and 4 h, and remained > 0.4 IU/ml for up to 10 h after injection, however, peak and hourly anti-Xa activities during dialysis were not measured. 11 In order to meet the needs of the elective PCI procedure in the present study, peak and hourly anti-Xa activities were checked using a slightly lower dose of enoxaparin (0.5 mg/kg) than that used by Guillet et al. 11 The results showed that this slightly lower intravenous dose provided satisfactory anticoagulation for the elective PCI procedure in the first 2 h after injection; the anti-Xa activity at the end of 2 h was also suitable for sheath removal. The levels of anti-Xa activity in the ESRD group at the peak (10 min after injection) and 1 h after injection were unexpectedly lower than those in the non-ESRD group. This discrepancy between the two groups might have resulted from the initial hypervolaemic status of the ESRD group.
In accordance with a previous study, 14 the extremely low rates of major adverse cardiovascular events (death, myocardial infarction and urgent target vessel revascularization) in the present study probably resulted from the initial selection of approachable coronary lesions. Approachable lesions were chosen so that a thorough evaluation of the changes of anti-Xa activity after a single injection of enoxaparin in a predictable procedure time could be made. The relatively short procedure time in the present study was probably a consequence of lesion selection. A single injection of enoxaparin (0.5 or 0.75 mg/kg), without the additional bolus used in the STEEPLE trial, remains the major practice (> 99%) in enoxaparin-treated
